conditions and other factors. Shares may be purchased on the open
market or through private transactions, pursuant to Rule 10b5-1 trading
plans or other available means. The Company repurchased approximately
$10 million of its stock in the third quarter.
Webcast Conference Call
A live webcast of Gen-Probe's third quarter 2008 conference call for investors can be accessed at http://www.gen-probe.com beginning at 4:30 p.m. Eastern Time today. The webcast will be archived for at least 90 days. A telephone replay of the call also will be available for approximately 24 hours. The replay number is (866) 505-9257 for domestic callers and (203) 369-1881 for international callers.
Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective NATs that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has approximately 25 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,000 people. For more information, go to http://www.gen-probe.com.
APTIMA, APTIMA COMBO 2, PACE and TIGRIS are trademarks of Gen-Probe. ULTRIO and PROCLEIX are trademarks of Novartis. All other trademarks are the property of their owners.
Caution Regarding Forward-Looking Statements
Any statements in this press release about our expectations, beliefs,
plans, objectives, assumptions or future events or performance, including
those under the heading "Updated 2008 Financial Guidance," are not
historical facts and are forward-looking statements. These statements are
often, but not always, made t
|SOURCE Gen-Probe Incorporated|
Copyright©2008 PR Newswire.
All rights reserved